We created a model to better understand the economics of Gigapower for both AT&T and Blackrock. Please use the model and give us your thoughts. The model clarifies the value of broadband assets generally. It also clarifies why we are likely to see similar JVs from Frontier, Lumen, and others. We will adapt this model for those instances in due course.
MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure’s management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, Inc....
AMN Healthcare Announces First Quarter 2024 Results Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97 DALLAS, May 09, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts. Q1 2024% Change Q1 2023Revenue$820.9(27%) Gross profit$257.5(30%) Net income$17.3(79%) GAAP diluted EPS$0.45(78%) Adjusted dilute...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate...
Survey: Nurses See Little Improvement in 2024 Over One-Third Extremely Likely to Change Jobs DALLAS, May 06, 2024 (GLOBE NEWSWIRE) -- The majority of nurses (80%) think 2024 will be either no better or worse for nurses than 2023, according to a new survey by AMN Healthcare, the nation’s leading healthcare workforce solutions company. Forty-two percent said 2024 will be the same for nurses as 2023, 38% said it will be worse, while only 20% said it will be better. “Nurses weathered the storm of COVID-19, but many still see clouds ahead for the profession,” said Robin Johnson, Group Presi...
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Industry net adds were substantially weaker in 1Q24 with all technologies seeing slower growth (except DSL which was flat). Cable was impacted the most.
MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “We remain diligently focused on expanding the reach of our solutions for patients with advanced forms of Afib, managing the LAA in patients undergoing cardiac sur...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL), (“Viking”), and (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology. The collaboration brings together Viking and ArrowMark’s expertise in early-stage investing and company creation with AbCellera’s for discovering and developing antibody medicines. Under the collaboration, ArrowMark and Viking will lead the initial process of program selection, followed by ...
MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference. AtriCure’s management is scheduled to present on Tuesday, May 14, 2024, at 10:15 a.m. Pacific Daylight Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, Inc. provides innovat...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Survey: Physicians Turning to Locum Tenens to Improve Work Conditions, Relieve Burnout Many Would Return to Permanent Positions If Conditions Right DALLAS, April 23, 2024 (GLOBE NEWSWIRE) -- Physicians and advanced practice professionals are opting for the flexibility of temporary, “locum tenens” work in order to improve job conditions and address feelings of burnout, according to a new survey by AMN Healthcare, the nation’s leading healthcare workforce solutions company. Latin for “to hold a place,” locum tenens refers to physicians and other clinicians who work on temporary assignmen...
MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with full launch expected by the end of the second quarter. “cryoSPHERE+ is a meaningful innovation that I believe will improve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.